

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 May 2001 (03.05.2001)

PCT

(10) International Publication Number
WO 01/30967 A2

- (51) International Patent Classification⁷: C12N (74) Agents: IHNEN, Jeffrey, L. et al.; Rothwell, Figg, Ernst & Manbeck, Suite 701 East, 555 13th Street N.W., Columbia Square, Washington, DC 20004 (US).
- (21) International Application Number: PCT/US00/29370
- (22) International Filing Date: 26 October 2000 (26.10.2000) (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/161,368 26 October 1999 (26.10.1999) US
- (71) Applicant (*for all designated States except US*): UNIVERSITY OF UTAH RESEARCH FOUNDATION [US/US]; Suite 110, 615 Arapeen Drive, Salt Lake City, UT 84108 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): GRISSOM, Charles, B. [US/US]; 2740 E. Comanche Drive, Salt Lake City, UT 84108 (US). WEST, Frederick, G. [US/US]; 998 S. 1500 East, Salt Lake City, UT 84105 (US). MCGREEVY, James [US/US]; 6532 S. Heughs Canyon Drive, Salt Lake City, UT 84121-6308 (US). BENTZ, Joel, S. [US/US]; 2102 E. Somerset Drive, Salt Lake City, UT 84121 (US).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/30967 A2

(54) Title: FLUORESCENT COBALAMINS AND USES THEREOF

(57) Abstract: The present invention relates to fluorescent cobalamins and uses of these compounds. More particularly, this invention relates to fluorescent cobalamins that comprise a fluorescent, phosphorescent, luminescent or light-producing compound covalently linked to cobalamin. These fluorescent cobalamins can be used as diagnostic and prognostic markers (a) to distinguish cancer cells and tissues from healthy cells and tissues and (b) to determine if an individual will respond positively to chemotherapy using cobalamin-therapeutic bioconjugates.

TITLE OF THE INVENTION

FLUORESCENT COBALAMINS AND USES THEREOF

This invention was made in part with Government support under Grant No. R01 CA73003
5 awarded by the National Institutes of Health, Bethesda, Maryland. The United States Government
has certain rights in the invention.

BACKGROUND OF THE INVENTION

The present invention relates to fluorescent cobalamins and uses of these compounds.
10 More particularly, this invention relates to fluorescent cobalamins comprised of a fluorescent,
phosphorescent, luminescent or light-producing compound that is covalently linked to
cobalamin. These fluorescent cobalamins can be used as diagnostic and prognostic markers (a)
to distinguish cancer cells and tissues from healthy cells and tissues and (b) to determine if an
individual will respond positively to chemotherapy using cobalamin-based therapeutic
15 bioconjugates.

The publications and other materials used herein to illuminate the background of the
invention, and in particular cases, to provide additional details respecting the practice, are
incorporated by reference, and for convenience are referenced in the following text by author
and date and are listed alphabetically by author in the appended bibliography.

20 Rapidly-dividing cells require cobalamin as a cofactor for the enzyme methionine
synthase to support one-carbon metabolism prior to DNA replication (Hogenkamp et al., 1999).
In acute promyelocytic leukemia, a 3-26 fold increase in the unsaturated B₁₂ binding capacity of
blood is observed, due to an increase in the concentration of the B₁₂ binding proteins
transcobalamin and haptocorrin (Schneider, et al., 1987; Rachimelwitz, et al., 1971). Some
25 patients with solid tumors also exhibit a significant increase in the circulating levels of
transcobalamin and haptocorrin (Carmel, et al., 1975). The increase in unsaturated serum
cobalamin binding capacity corresponds to the increased uptake of cobalamin by rapidly
dividing cells. Tumors even sequester sufficient cobalamin for diagnostic imaging purposes if a
gamma-emitting radionuclide, such as ¹¹¹In, is attached to cobalamin through the octadentate
30 chelator diethylenetriaminepentaacetic acid (DTPA) (Hogenkamp and Collins, 1997). This has
been demonstrated in mice with an implanted fibrosarcoma (Hogenkamp and Collins, 1997), as
well as in humans with breast cancer (Collinset al., 1999), and in tumors of the prostate, lung,
and brain (Collins et al., 2000).

-2-

In the sentinel lymph node concept for melanoma and breast cancer surgery, a dye or radionuclide is injected into the tissue around the tumor to identify the first lymph node that drains the tumor (Morton et al., 1992; McGreevy, 1998). This node is termed the sentinel node, and it is removed for diagnostic tests to determine the extent of metastasis beyond the primary tumor. This procedure is controversial, as it fails to detect metastatic disease in about 12% of patients (McMasters et al., 1999). The dye or radionuclide that is injected is not specific for cancer cells, but merely identifies for the surgeon the primary lymph node that drains the region of the tumor. The high false-negative rate should be improved dramatically by using a fluorescent marker that is specific for cancer cells.

Thus, there exists a need for an agent that can be used for the diagnosis and prognosis of cancer tissue or cells with improved results.

SUMMARY OF THE INVENTION

The present invention relates to fluorescent cobalamins and uses of these compounds. More particularly, this invention relates to fluorescent cobalamins comprised of a fluorescent, phosphorescent, luminescent or light-producing compound that is covalently linked to cobalamin. These fluorescent cobalamins can be used as a diagnostic and prognostic marker (a) to distinguish cancer cells and tissues from healthy cells and tissues and (b) to determine if an individual will respond positively to chemotherapy using cobalamin-therapeutic bioconjugates. The fluorescent cobalamins of the present invention offer the necessary properties of (1) rapid transport and storage by cancer cells (maximum uptake occurs at 4-6 hours), (2) a bright fluorophore that can be visually detected at very low concentrations, and (3) nontoxic components.

In one aspect of the present invention, fluorescent cobalamins are provided in which fluorescent, phosphorescent, luminescent or light-producing compounds are covalently linked to cobalamin (vitamin B₁₂). The fluorescent, phosphorescent or light-producing compounds can be covalently linked to the cobalt atom, the corrin ring, or the ribose moiety of cobalamin. It is preferred to covalently link the fluorescent, phosphorescent, luminescent or light-producing compound to the corrin ring or the ribose moiety. Although, any fluorescent, phosphorescent, luminescent or light-producing compound can be utilized in preparing the fluorescent cobalamins, it is preferred to utilize fluorescent, phosphorescent, luminescent or light-producing compounds that are excitable with visible or infrared light. Examples of preferred fluorescent

compounds include, but are not limited to, fluorescein, fluorescein-5EX, methoxycoumarin, naphthofluorescein, BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY TR, Cascade Blue, Dansyl, Dialkylaminocoumarin, 4',5'-dichloro-2',7'-dimethoxyfluorescein, 2',7'-dichlorofluorescein, eosin, eosin F3S, erythrosin, hydroxycoumarin, lissamine rhodamine B, methoxycoumarin, naphthofluorescein, NBD, Oregon Green 488, Oregon Green 500, Oregon Green 514, PyMPO, pyrene, rhodamine 6G, rhodamine green, rhodamin red, rhodol green, 2',4',5',7'-tetrabromosulfonefluorescein, tetramethylrhodamine (TMR), Texas Red, X-rhodamine, Cy2 dye, Cy3 dye, Cy5 dye, Cy5.5 dye, or a quantum dot structure. The preferred fluorescent cobalamins of the present invention fluoresce when excited by visible or infrared light without the need to separate the fluorescent or phosphorescent compound from cobalamin.

In a second aspect of the present invention, the fluorescent cobalamins are used to distinguish cancer cells from healthy cells. In one embodiment of this aspect of the invention, a fluorescent cobalamin is administered to a patient prior to surgery. The presence of fluorescence, phosphorescence, luminescence or emitted light in cancer cells is used by the surgeon to define the tissue to be removed, whether in a primary tumor or in a metastatic site. In a second embodiment, a fluorescent cobalamin is administered to a patient in a manner suitable for uptake by lymph nodes draining the *situs* of the tumor. The presence of fluorescence, phosphorescence, luminescence or emitted light identifies those lymph nodes that should be removed during surgery.

In a third aspect of the present invention, the fluorescent cobalamins are used to determine if an individual will respond positively to chemotherapy using cobalamin-based therapeutic bioconjugates. In this aspect, a fluorescent cobalamin is used to assess the ability of the particular cancer cell type to transport and store cobalamin, both qualitatively and quantitatively. Various types of cancer that transport and store large amounts of cobalamin are good candidates for therapy with cobalamin-based therapeutic bioconjugates. Quantification of tumor cell cobalamin binding, uptake, transport, and storage can be carried out by measuring the fluorescence under visual inspection (e.g. tissue slide), by epifluorescence microscopy, or by flow cytometry.

In a fourth aspect of the present invention, the fluorescent cobalamins are used to determine the levels of cobalamin in blood, plasma, serum, cerebrospinal fluid or urine or to

determine the amount of unbound cobalamin binding capacity in blood, plasma, serum or cerebrospinal fluid.

BRIEF DESCRIPTION OF THE DRAWINGS

5 Figure 1 shows the synthesis of one fluorescent cobalamin in accordance with the present invention.

 Figure 2 shows the synthesis of cobalamin monocarboxylic acids.

 Figure 3 shows the conjugation of cobalamin carboxylic acids with 1,12-diaminododecane.


10 Figure 4 shows conjugation of fluorescein-5EX-NHS ester with the diaminododecane cobalamin derivative.

 Figure 5 shows the fluorescence emission spectrum of fluorescein-5EX-b-cobalamin derivative CBC-123.

15 DETAILED DESCRIPTION OF THE INVENTION

 The present invention relates to fluorescent cobalamins and uses of these compounds. More particularly, this invention relates to fluorescent cobalamins that comprise a fluorescent compound (fluorophore), a phosphorescent compound (phosphorophore), a luminescent compound (chemiluminescent chromophore) or a light-producing compound that is covalently
20 linked to cobalamin (vitamin B₁₂). These fluorescent cobalamins can be used as diagnostic and prognostic markers (a) to distinguish cancer cells and cancerous tissue from healthy cells and tissues and (b) to determine if an individual will respond positively to chemotherapy using cobalamin-therapeutic bioconjugates.

 The fluorescent cobalamins of the present invention can be represented by the following
25 formula



where R_1 is CN, OH, OH_2 , CH_3 , 5'-deoxyadenosine or $(\text{CH}_2)_p\text{NHC}(=\text{S})\text{Y}$; R_2 , R_3 , R_4 , R_5 , R_6 , and R_7 are independently CONH_2 or $\text{CO-X}_m\text{Y}$; R_8 is CH_2OH or $\text{O}(\text{C}=\text{O})\text{X}_m\text{Y}$; R_9 is OH or $\text{O}(\text{C}=\text{O})\text{X}_m\text{Y}$; X is a linker having the formula $\text{N}(\text{CH}_2)_n\text{NHO}(\text{C}=\text{O})$; Y is a fluorophore, a phosphorophore, chemiluminescent chromophore or a light-producing molecule; m is 0 or 1, n is 0-50 and p is 2-10, with the proviso that at least one of $R_1 - R_9$ groups contains Y.

The fluorescent cobalamins of the present invention are prepared by covalently attaching a fluorophore, a phosphorophore, chemiluminescent chromophore or a light-producing molecule to cobalamin. The fluorophore, phosphorophore, chemiluminescent chromophore or light-producing molecule is covalently linked to the cobalt atom, to the corrin ring or to the ribose sugar directly or via a linker molecule. The covalent linkage is preferably accomplished with the use of a linker molecule. If the fluorophore, phosphorophore, chemiluminescent chromophore or light-producing molecule is attached to the cobalt atom of cobalamin, the fluorescence, phosphorescence or emitted light is diminished in intensity through quenching by the spin of the cobalt atom. In addition, prolonged exposure of the fluorescent cobalamin to light will cleave the cobalt-carbon bond and release the fluorophore, phosphorophore, chemiluminescent

chromophore or light-producing molecule from cobalamin (Howard et al., 1997). Thus, it is preferred to attach the fluorophore, phosphorophore, chemiluminescent chromophore or light-producing molecule to the corrin ring or the ribose moiety of the cobalamin molecule. These latter fluorescent cobalamins do not have the disadvantages of the fluorescent cobalamins in which the fluorophore, phosphorophore, chemiluminescent chromophore or light-producing molecule is covalently linked to the cobalt atom.

Attachment of the fluorophore, phosphorophore, chemiluminescent chromophore or light-producing molecule to a carboxylate on the corrin ring or the 5'-ribose hydroxyl group circumvents the problem of lower sensitivity and photolability. In general, corrin ring carboxylate derivatives (Collins and Hogenkamp, 1997) are known, but none of the compounds synthesized have contained a fluorescent marker. The fluorophore, phosphorophore, chemiluminescent chromophore or light-producing molecule can be attached directly to the corrin ring, rather than to the cobalt atom by derivatization of the cobalamin monocarboxylate according to published methods (Collins and Hogenkamp, 1997 and references cited therein).

Although, any fluorophore, phosphorophore, chemiluminescent chromophore or light-producing molecule can be utilized in preparing the fluorescent cobalamins, it is preferred to utilize fluorophores that are excitable with visible or infrared light. It is preferred to use visible or infrared light for *in vivo* use of the fluorescent cobalamins. Examples of preferred fluorophores include, but are not limited to, fluorescein, fluorescein-5EX, methoxycoumarin, naphthofluorescein, BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY TR, Cascade Blue, Dansyl, Dialkylaminocoumarin, 4',5'-dichloro-2',7'-dimethoxyfluorescein, 2',7'-dichlorofluorescein, eosin, eosin F3S, erythrosin, hydroxycoumarin, lissamine rhodamine B, methoxycoumarin, naphthofluorescein, NBD, Oregon Green 488, Oregon Green 500, Oregon Green 514, PyMPO, pyrene, rhodamine 6G, rhodamine green, rhodamine red, rhodol green, 2',4',5',7'-tetrabromosulfonethylfluorescein, tetramethylrhodamine (TMR), Texas Red, X-rhodamine, Cy2 dye, Cy3 dye, Cy5 dye, Cy5.5 dye, or a quantum dot structure. The preferred fluorescent cobalamins of the present invention fluoresce when excited by visible or infrared light without the need to cleave the fluorophore from the bioconjugate.

It has been found that there is differential uptake of fluorescent cobalamin analogues in normal and leukemic human bone marrow. The difference between normal marrow cells and leukemic myeloblasts (cancer cells) is particularly noteworthy, with no detectable cobalamin

-7-

being taken up by normal cells. Bone marrow samples from healthy individuals show no fluorescent labeling. It has also been found that there is uptake of a doxorubicin-cobalamin conjugate, originally synthesized as a potential chemotherapeutic compound. Cellular uptake of the doxorubicin-cobalamin conjugate can be observed in P-388 murine leukemia cells, as well as
5 in HCT-116 human colon tumor cells. Thus, the uptake of fluorescent derivatives of cobalamin occurs in leukemia and solid tumor cell lines. These results, in combination with the knowledge that all cancer cells increase cobalamin transport and storage, demonstrate the general applicability of the use of fluorescent cobalamins to distinguish cancer cells from normal cells.

Thus, the fluorescent cobalamins of the present invention can be used to:

- 10 • identify cancerous tissue visually, via fluorescence microscopy, or by flow cytometry;
- identify cancerous cells in tissue sections or samples from tissue biopsies;
- define tumor margins *in vivo*, *ex vivo* or *in situ*;
- diagnose, detect, prognose, predict or monitor cancer *in vivo*, *ex vivo* or *in situ*;
- identify metastatic cancer *in vivo*, *ex vivo* or *in situ*;
- 15 • determine the stage of cancer progression;
- identify cancer transdermally;
- identify metastatic cancer transdermally;
- identify cancer in lymph nodes, including in the sentinel lymph node or nodes or in an axillary lymph node or nodes;
- 20 • identify metastatic disease in the treatment, detection, prediction, prognostication or monitoring of cancer, such as breast cancer, ovarian cancer, lung cancer, prostate cancer, epithelial cancer (adenocarcinoma), liver cancer, melanoma and lymphoma;
- conduct flow cytometry studies of bone marrow aspirates or peripheral blood samples for diagnosing, predicting, prognosticating, monitoring or characterizing leukemia or
25 lymphoma;
- predict whether a patient will respond positively to chemotherapy that is based on the use of a cobalamin-therapeutic bioconjugate,
- improve the definition of tumor micromargins in a biopsy or lumpectomy;
- decrease the chance of leaving cancerous cells behind in a biopsy, lumpectomy, or
30 tumorectomy and thereby reduce the need for follow-up surgery to remove the remaining cancer cells.

-8-

Prediction refers to understanding the biological behavior of the tumor, and how the tumor will respond (favorably or unfavorably) to therapy. Prognosis refers to the anticipated patient outcome following therapy (i.e. what is the likelihood of five- or ten-year survival following therapy). Monitoring refers to determining the success of therapy and detection of residual disease following treatment. An example is the use of a fluorescent cobalamin conjugate to test the bone marrow for the presence of myeloblasts following treatment of leukemia. Characterization refers to a descriptive or quantitative classification of the type of tumor in comparison to closely related types of tumors.

The fluorescent cobalamins of the present invention can be administered in accordance with customary cancer diagnostic, detection, prediction, prognostication, monitoring or characterization methods known in the art. For example, the fluorescent cobalamins can be administered intravenously, intrathecally, intratumorally, intramuscularly, intralymphatically, or orally. Typically, an amount of the fluorescent cobalamin of the present invention will be admixed with a pharmaceutically acceptable carrier. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral, parenteral, intravenous, intrathecal, intratumoral, circumtumoral, and epidural. The compositions may further contain antioxidizing agents, stabilizing agents, preservatives and the like. Examples of techniques and protocols can be found in *Remington's Pharmaceutical Sciences*. The amount of fluorescent cobalamin to be administered will typically be 1-500 mg.

An improvement in the surgeon's ability to identify metastatic disease in lymph nodes will advance surgical therapy by preserving, e.g., healthy tissue and minimizing the number of axillary lymph nodes removed. This will improve the patient's quality of life and improve morbidity and long-term mortality. Precise identification of cancer cells that have spread to lymph nodes will allow removal of only the diseased ducts and nodes, while sparing the healthy axillary nodes. This invention is extremely valuable. For example, with 186,000 new cases of breast cancer each year, the number of surgeries to remove primary tumors and determine the status of associated lymph nodes is significant. The perfunctory removal of all axillary lymph nodes and ducts leads to local edema and increased morbidity. The non-removal of axillary lymph nodes and ducts that contain metastatic cancer cells leads to decreased survival and increased long-term mortality.

In the sentinel lymph node biopsy approach, a blue dye and/or radioactive tracer are injected into the breast near the tumor. A small incision is made under the arm to look for traces

of the dye or radioactivity to identify the lymph node(s) that drain the area of the breast and, as a consequence, are most likely to contain metastatic cancer cells. In accordance with the present invention, a fluorescent cobalamin replaces the blue dye and radioisotope tracer currently used in sentinel lymph node biopsies. The use of the fluorescent cobalamins of the present invention
5 may enable the future application of the sentinel lymph node biopsy approach to all types of cancer.

In addition, since the fluorescent cobalamins of the present invention are differentially taken up by cancer cells, these fluorescent cobalamins are an improved marker that will allow surgeons to excise cancerous tissue selectively, thereby leaving healthy tissue.

10 The fluorescent cobalamins of the present invention offer several improvements as an intraoperative marker. These improvements include:

- The fluorescent marker will be specific for cancer cells in lymph ducts and nodes, rather than simply indicating which node is draining the tidal basin. The fluorescent marker will also distinguish cancer cells from healthy cells.
- 15 • The marker can be used in low concentrations because of the inherent sensitivity afforded by fluorescence detection. The blue dye now in use tends to obscure the active node and complicates postsurgical examination of the tissue by a pathologist. The blue dye also tends to obscure bleeding vessels, thereby complicating surgical excision of the node and subsequent wound closure. The use of a fluorescent marker should avoid these problems.
- 20 • A fluorescent marker that is specific for cancer cells will improve the false-negative rate of 5-10% as is seen with the procedure as currently practiced.
- A decreased false-negative rate would improve the acceptance of this technique by patients and surgeons. This might decrease the training time necessary (typically 30 or more cases with complete axial node dissection) for a surgeon to learn this procedure.

25 In a further embodiment of the present invention, the fluorescent cobalamins can be used in a competitive binding assay to determine the concentration or amount of naturally-occurring cobalamin (hydroxocobalamin, methylcobalamin, adenosylcobalamin, or cyanocobalamin) in blood, plasma, serum, or other bodily fluids. In this type of assay, a fluorescent cobalamin is used in place of radioactively-labelled cobalamin in a competitive binding assay, well known to
30 a skilled artisan. Radioactive assays for cobalamin have been described in U.S. Patent Nos. 6,096,290; 5,614,394; 5,227,311; 5,187,107; 5,104,815; 4,680,273; 4,465,775; 4,355,018, among others, each incorporated herein by reference. This assay procedure can be used to

-10-

determine the amount of unsaturated cobalamin binding capacity in blood, plasma, serum, or bodily fluids, as well as the concentration of cobalamin that is bound to the proteins transcobalamin, haptocorrin, or intrinsic factor. The use of fluorescent cobalamins has a significant advantage over radioactively-labelled cobalamin in a clinical chemistry binding assay because it does not require the special shipping, handling, and disposal procedures associated with radioactively-labelled cobalamin.

EXAMPLES

The present invention is further described by reference to the following Examples, which are offered by way of illustration and are not intended to limit the invention in any manner. Standard techniques well known in the art or the techniques specifically described below were utilized.

EXAMPLE 1

Synthesis of Fluorescent Cobalamin by Attachment of the Fluorophore to Cobalt

As a visual indicator of cobalamin localization, five fluorescent analogues of cobalamin were prepared by covalently attaching fluorescein to cobalamin. Under green light illumination, the fluorescein molecule emits yellow light that can be detected by the dark-adapted eye to concentrations lower than 0.1 ppm. This emission enables the sensitive detection of cancer cells via epifluorescence microscopy, as well as by visual inspection. Each of the five fluorescent cobalamins exhibited intrinsic fluorescence. All of these compounds were synthesized by reacting aminopropyl chloride with cob(I)alamin to produce aminopropylcob(III)alamin in accordance with published techniques. In a subsequent step, aminopropylcob(III)alamin was reacted with a variety of fluorophore isothiocyanates (i.e. fluorescein isothiocyanate, "FITC") to produce the corresponding fluorophore that is linked to cobalamin through an aminopropyl linker (i.e. fluorescein-aminopropyl-cob(III)alamin) This latter reaction is shown in Figure 1.

In a similar manner, fluorescent cobalamins were prepared in which the fluorophore is naphthofluorescein or Oregon Green. All the fluorescent cobalamins were found to retain high affinity for recombinant transcobalamin (rhTCII), thus allowing for a biological distribution similar to that observed for naturally occurring cobalamin.

-11-

EXAMPLE 2

Uptake of Cobalamin Analogues by Cancer Cells

A leukemic myeloblast preparation was made from a bone marrow aspirate of a 61-year old patient having acute myelogenous leukemia (AML) M1 (minimally mature myeloblasts in the FAB classification). Cells were treated three days post-harvest with a fluorescent cobalamin prepared as described in Example 1. Differential uptake of fluorescent cobalamin analogues, as determined by fluorescence microscopy or fluorescence flow cytometry, in normal and leukemic human bone marrow cells was found. The difference between normal marrow cells and leukemic myeloblasts (cancer cells) is particularly noteworthy, with no detectable cobalamin being taken up by normal cells. A bone marrow sample from a healthy individual showed no fluorescent labeling. Uptake of a doxorubicin-cobalamin conjugate, originally synthesized as a potential chemotherapeutic compound, was seen in P-388 murine leukemia cells and in HCT-116 human colon tumor cells. These results illustrate the uptake of fluorescent derivatives of cobalamin in leukemia and solid tumor cell lines.

15

EXAMPLE 3

Preparation of Cyanocobalamin Monocarboxylic Acids

The b-, d-, and e-monocarboxylic acids were prepared by acid-catalyzed hydrolysis of cyanocobalamin. See Figure 2. Briefly, cyanocobalamin (527.0 mg, 0.389 mmol) was placed into a 100 ml round bottom flask and dissolved in 40 ml of 0.5 M HCl. The flask was placed in a water bath at 50 °C and stirred for 4 hours. The reaction was monitored via HPLC (Waters, Inc. 3.9 x 300mm DeltaPak 100 C-18 column) using the gradient tabulated in Table 1.

20

-12-

TABLE 1

Time (min)	Flow Rate (ml/min)	0.5 M H ₃ PO ₄ (pH 3.0 w/ NH ₃ OH)	9:1 CH ₃ CN: H ₂ O
0.0	2.0	90.0	10.0
2.0	2.0	90.0	10.0
18.0	2.0	83.7	16.3
23.0	2.0	30.0	70.0
25.0	2.0	30.0	70.0
30.0	2.0	90.0	10.0

After 4 hours the reaction was cooled to room temperature. The pH was adjusted to 7.0 with NaOH (10%) using a pH meter. The crude material was desalted using a C-18 SepPak column (Waters, Inc. P/N WATO23635) by first rinsing the column with 10 ml methanol followed by 15 ml deionized H₂O. The crude material was applied to the column via a syringe and rinsed with 10-15 ml deionized H₂O followed by elution with 10 ml methanol. The methanol was removed via rotary evaporation and a red compound was obtained (5016-12-33).

The crude reaction mixture was dissolved in minimal deionized H₂O and half of the solution was injected onto a semi-preparative HPLC (Waters, Inc. 25.0x300mm 100 C-18 column) using the gradient calculated in Table 2.

TABLE 2

Time (min)	Flow Rate (ml/min)	0.5 M H ₃ PO ₄ (pH 3.0 w/ NH ₃ OH)	9:1 CH ₃ CN: H ₂ O
0.0	40.0	90.0	10.0
4.1	40.0	90.0	10.0
37.0	40.0	83.7	16.3
47.3	40.0	30.0	70.0
51.4	40.0	30.0	70.0
61.6	40.0	90.0	10.0

-13-

Peaks at 28.0 min (b-monocarboxylic acid, CBC-195), 30.1 min (d-monocarboxylic acid, CBC-226) and 34.6 min (e- monocarboxylic acid) were collected using large test tubes. The pure fractions were diluted 1:1 with deionized H₂O and desalted in the same method above. In all cases, a red solid was obtained.

5 CBC-195 (b-monocarboxylic acid): In the two preparative runs, 74.8 mg of the b-monocarboxylic acid (14.4 %) was isolated. A positive-ion electrospray mass spectrum (ES⁺) was obtained that shows a M+1 peak (1356) and a M+22 peak (1378) as expected. The b-monocarboxylic acid (CBC-195) was obtained in an overall yield of 14%

10 CBC-226 (d-monocarboxylic acid): In the two prep. runs, 38.6 mg of the d-monocarboxylic acid (7.3%) was isolated. A positive-ion electrospray mass spectrum (ES⁺) was obtained showing a M+1 peak (1356) and the corresponding M+Na peak (1378) as expected. The d-monocarboxylic acid (CBC-226) was obtained in an overall yield of 7%

The e-monocarboxylic acid was isolated, ~78 mg in an overall yield of 14%.

15

EXAMPLE 4

Conjugation of CNCbl Acids with 1,12 Diaminododecane

The b- and d- amines were prepared as shown in Figure 3. CBC-195 (55.4 mg, 0.0408 mmol) was added to a small glass vial and dissolved in ~2.5 ml of DMSO followed by the addition of EDCI·HCl (12mg, 0.0626 mmol) and N-hydroxysuccinimide (NHS) (25 mg, 0.217 mmol). The reaction was stirred at room temperature overnight. From previous attempts, several equivalents of EDCI and NHS (a total of 6 equivalents) were required to drive the reaction to completion. After 24 hours, one additional equivalent of EDCI was added and the reaction was complete in a total of 26 hours. The reaction was monitored via HPLC using the gradient is Table 3. CBC-195 has a retention time of 9.07 min and the NHS-ester of CBC-195 has a retention time of 10.55 min.

20

25

-14-

TABLE 3

Time (min)	Flow Rate (ml/min)	0.5 M H ₃ PO ₄ (pH 3.0 w/ NH ₃ OH)	9:1 CH ₃ CN: H ₂ O
0.0	2.0	90.0	10.0
2.0	2.0	90.0	10.0
20.0	2.0	55.0	45.0
25.0	2.0	9.0	10.0

In a separate glass vial, 1,12-diaminododecane (81.8 mg, 0.408 mmol) was dissolved in ~2 ml DMSO. The above reaction mixture was added dropwise using a syringe pump at 4.0 ml/hr to minimize dimerization. The product was formed immediately and has a retention time of 14.56 min. The crude reaction mixture was added to 100 ml of 1:1 CH₂Cl₂:Et₂O and a red precipitate formed. The red compound was filtered using a glass frit and washed with two 20 ml portions of CH₂Cl₂, two 20 ml portions of acetone, and finally by two 20 ml portions of Et₂O.

The crude reaction product was dissolved in a minimal amount of deionized H₂O and the solution was injected onto a semi-preparative HPLC (Waters, Inc., 25.0x100mm 100 C-18 column) using the gradient calculated in Table 4.

TABLE 4

Time (min)	Flow Rate (ml/min)	0.5 M H ₃ PO ₄ (pH 3.0 w/ NH ₃ OH)	9:1 CH ₃ CN: H ₂ O
0.0	40.0	90.0	10.0
2.0	40.0	90.0	10.0
13.7	40.0	55.0	45.0
17.1	40.0	90.0	10.0

The peak at 8.70 min (b-amine, CBC-208) was collected using large test tubes. The pure fractions were diluted 1:1 with distilled H₂O and desalted using a C-18 SepPak column (Waters, Inc. P/N WATO23635) by first rinsing the column with 10 ml methanol followed by 15 ml deionized H₂O. The pure material was applied to the column via a syringe and rinsed with 10-15

-15-

ml deionized H₂O followed by elution with 10 ml methanol. The methanol was removed via rotary evaporation and 6 mg of a red compound was obtained.

CBC-208 (b-amine): A total of 6.0 mg of the b-amine was isolated. A positive-ion electrospray mass spectrum (ES⁺) was obtained that shows a M+1 peak (1538) and a M+23 peak (1560) as expected. CBC-208 was obtained in a yield of 9.5% after purification.

CBC-226 (d-amine): The d-monocarboxylic acid has an HPLC retention time of 9.32 min, the NHS-ester migrates at 10.96 min, and the d-amine (CBC-226) migrates at 14.93 min using the same HPLC gradient as in Table 3. A positive-ion electrospray mass spectrum (ES⁺) was obtained of the crude material showing a M+1 peak (1538) and the corresponding M+Na peak (1560) as expected.

EXAMPLE 5

Conjugation of CBC-208 and Fluorescein-5EX-NHS

CBC-208 has been coupled to the fluorescein derivative fluorescein-5EX (available from Molecular Probes, Inc.) according to Figure 4. CBC-208 (6.0 mg, 3.87 μmol) was added to a small glass vial and dissolved in ~0.5 ml of DMSO followed by the addition of fluorescein-5EX-NHS (2.5 mg, 4.23 μmol). The reaction was allowed to stir at room temperature overnight. The reaction was monitored via HPLC using the method in Table 5.

TABLE 5

Time (min)	Flow Rate (ml/min)	0.5 M H ₃ PO ₄ pH 3.0 w/ NH ₃ OH	9:1 CH ₃ CN: H ₂ O
0.0	2.0	90.0	10.0
2.0	2.0	90.0	10.0
10.0	2.0	65.0	35.0
15.0	2.0	5.0	95.0
28	2.0	90.0	10.0

The reaction proceeded very quickly initially forming the desired product after only 10 minutes of contact. CBC-208 has a retention time of 11.47 min and the product (CBC-123) has a retention time of 14.24 min. With the addition of another equivalent of the fluorescein compound the reaction goes to completion and the crude mixture is 88% pure.

-16-

HPLC analysis of the starting material fluorescein-5EX-NHS shows that it is only 75% pure, which explains why an additional equivalent was necessary in order to drive the reaction to completion.

CBC-123 (b-fluorescein cobalamin derivative): This compound is nearly 90% pure as the crude isolate from the synthesis, with the majority of the impurity being unreacted CBC-208. A positive-ion electrospray mass spectrum (ES⁺) was obtained of the crude material showing a M+1 peak (2013) and the corresponding M+Na peak (2035). The yield before purification is 22%.

A fluorescence spectrum of this compound was taken of the crude compound before and after photolysis with excitation at 350 nm (see Figure 5). There is no significant change in fluorescence before and after photolysis suggesting that the compound is photostable and is overtly fluorescent and does not exhibit diminished fluorescence from the proximity of cobalamin.

EXAMPLE 6

Ex vivo Examination of Breast Tumor Tissue via Microscopy

Samples of malignant and benign tumors, including tumors of the breast, with attached normal margin tissue are excised from patients. These samples are taken with approval of the University of Utah Institutional Review Board (IRB) and the Huntsman Cancer Institute Clinical Cancer Investigation Committee (CCIC). The live tissue samples are incubated with one of the fluorescent cobalamin derivatives prepared above for 4-6 hours. Thin tissue sections of each sample are prepared with a cryomicrotome and the amount of fluorescent marker is quantified in normal and cancerous tissue by epifluorescence microscopy. Corresponding tissue sections are stained with hematoxylin/eosin (H&E) stain for evaluation by an anatomical pathologist. The interface between normal and cancerous cells is examined carefully. Cells from the interior of the tumor are also examined for uptake of fluorescent marker, since cells within hypoxic regions of a tumor often have decreased metabolism.

More specifically, Minimum Essential Medium, alpha modification (α -MEM; 7.5% newborn calf serum, 2.5% fetal bovine serum, 0.2% nystatin, 2.5% penicillin/streptomycin, pH7.2; Sigma) was prepared and aliquoted (10 mL) into sterile 25 mL screw top tissue culture flasks. The media was brought to 37 °C, and tissue samples were incubated with fluorescently labeled cobalamins (50 nM; cobalamin-Oregon Green and cobalamin-naphthofluorescein

-17-

conjugates of Example 1 and cobalamin-fluorescein conjugate of Example 5) and recombinant human TCII (50 pM) in α -MEM for 3 hours. Human breast tissue samples were procured under an IRM-approved protocol. The tissue was removed from the flask, washed with Dulbecco's Phosphate Buffered Saline (DPBS; Sigma), and mounted on a brass plate at -20°C with OCT compound (Shandon) for frozen section slicing. Tissue was sliced (4-6 μm sections) in a CTD Harris cryostat at -20°C . Thin tissue sections were pulled back with a small artist brush and fixed to a microscope slide with 100% ethanol. Slides were stained using a standard hematoxylin staining procedure: 95% ethanol, 20 seconds; water, 5 seconds; hematoxylin (Fisher), 45 seconds; water, 5 seconds; bluing solution (tap water), 10 seconds; 95% ethanol, 10 seconds; 100% ethanol, 10 seconds; xylene, 10 seconds; and xylene, 10 seconds. Slides were evaluated by phase contrast and epifluorescence microscopy at 10x, 60x and 100x magnification.

3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium thiazolyl bromide (MTT; Sigma) was used to qualitatively determine the metabolic competency of the tissue after 3 hours incubation time with fluorescent cobalamin. A portion of the tissue was removed from the media, washed with DPBS, and immersed in MTT (2 mL; 2.5 mg/mL). This tissue was incubated for 3 hours under a 5% CO_2 atmosphere at 37°C . During this incubation period, viable cells in the tissue sample reduced the MTT dye to purple formazan by succinate dehydrogenase activity (Celis and Celis, 1998). The tissue was washed with DPBS and prepared according to the cryomicrotome procedure outlined above to ensure the metabolic competency of the tissue.

The fluorescent cobalamin bioconjugates accumulated to some extent in both neoplastic and healthy breast tissue, with the neoplastic breast tissue sequestering more fluorescent cobalamin than healthy breast tissue. The amount of fluorescent cobalamin sequestered by healthy breast tissue is larger than expected, but it is believed that it is due to non-specific binding to structures within connective tissue rather than to significant internalization by healthy cells.

EXAMPLE 7

Ex vivo Examination of Cancer Cells in Lymph Nodes

Excised lymph nodes with metastatic disease are removed from patients and incubated for 4-8 hours with one of the fluorescent cobalamin derivatives prepared above. Each lymph node is sectioned and examined microscopically for transport of the fluorescent cobalamin into

cancer cells. This experiment showed the ability of metastatic cells within lymph nodes to take up sufficient fluorescent cobalamin for imaging and visualization.

EXAMPLE 8

5 Use of Fluorescent Cobalamin to determine whether a patient will
respond favorably to chemotherapy with a cobalamin-based therapeutic bioconjugate

A bone marrow aspirate or a peripheral blood sample from a patient with leukemia is incubated with a fluorescent cobalamin conjugate. After 4-8 hours, bone marrow aspirate or peripheral blood sample is washed to remove unincorporated fluorescent label and the cell
10 sample subjected to qualitative or quantitative fluorescence analysis by epifluorescence microscopy or flow cytometry. Cells that have taken up a significant amount of fluorescent cobalamin exhibit a brighter fluorescence. The uptake of a significant amount of fluorescent cobalamin indicates that the type of leukemia the patient has will respond favorably to treatment with a cobalamin-based therapeutic. A bone marrow aspirate or a peripheral blood sample that
15 does not show significant fluorescence after treatment with a fluorescent cobalamin conjugate indicates that the patient will not respond favorably to a cobalamin-based therapeutic conjugate. A similar approach can be applied to solid tumors. In this case, a portion of the excised tumor tissue is incubated with the fluorescent cobalamin conjugate and, after about 4-8 hours, fluorescence in the tumor tissue is quantified. The greater fluorescence exhibited by the tumor
20 tissue, the greater the likelihood that the cancer will respond favorably to treatment with a cobalamin-based chemotherapeutic.

It will be appreciated that the methods and compositions of the instant invention can be incorporated in the form of a variety of embodiments, only a few of which are disclosed herein.
25 It will be apparent to the artisan that other embodiments exist and do not depart from the spirit of the invention. Thus, the described embodiments are illustrative and should not be construed as restrictive.

LIST OF REFERENCES


- 30 Carnici, R. (1975). "Extreme Elevation of Serum Transcobalamin I in Patients with Metastatic Cancer." *New Engl. J. Med.* **292**:282-284.
Celis, A. and Celis, J.E. (1998). *Cell Biology*, pp. 9-11.

- Collins, D. A. and Hogenkamp, H. P. C. (1997). "Transcobalamin II Receptor Imaging via Radiolabeled Diethylene-Triaminepentaacetate Cobalamin Analogs." *J. Nucl. Med.* **38**:717-723.
- Collins, D.A. et al. (1999). "Tumor Imaging via Indium-111-Labeled DTPA-Adenosylcobalamin." *Mayo Clinic Proceedings* **74**: 687-691.
- Collins, D.A. et al. (2000). "Biodistribution of Radiolabeled Adenosylcobalamin in Patients Diagnosed with Various Malignancies." *Mayo Clinic Proceedings* **75**:568-580.
- Flodh, H. (1968). "Accumulation of labelled Vitamin B-12 in Some Transplanted Tumors." *Acta Radiol. Suppl.* **284**:55-60.
- Hogenkamp, H. P.C., et al. (1999). "The Pharmacological Uses of Cobalamin Bioconjugates." In *The Chemistry and Biochemistry of B-12*, Banerjee, R., Ed., John Wiley & Sons, New York, pp. 385-410.
- Howard, W.A. et al. (1997). "Sonolysis Promotes Indirect C-Co Bond Cleavage of Alkylcob(III)alamins." *Bioconj. Chem.* **8**:498-502.
- McGreevy, J. M. (1998). "Sentinel Lymph Node Biopsy in Breast Cancer." *Curr. Surg.* **55**:301-4.
- Mitchell, A. M. et al. (1999). "Targeting Leukemia Cells with Cobalamin Bioconjugates" In *Enzymatic Mechanisms*, Frey, P. A.; Northrop, D. B., Eds., pp 150-154.
- McMasters, K. M. et al. (1999). "Sentinel Lymph Node Biopsy for Breast Cancer -- Not yet the Standard of Care." *New England J. Med.* **339**:990.
- Morton, D. L. et al. (1992). "Technical Details of Intraoperative Lymphatic Mapping for Early Stage Melanoma." *Arch. Surg.* **127**:392-9.
- Rachmilewitz, B, et al. (1971). , "Serum Transcobalamin in Myeloid Leukemia." *J. Lab. Clin. Med.* **78**:275.
- Schneider, Z. and Stroinski, A. (1987). *Comprehensive B12*, de Gruyter, Berlin, pp. 358.

WHAT IS CLAIMED IS:

1. A fluorescent cobalamin that comprises a fluorophore, a phosphorophore, a chemiluminescent chromophore or a light-producing molecule covalently linked to an atom in cobalamin, wherein said fluorescent cobalamin fluoresces, phosphoresces, luminesces or emits light when illuminated with ultraviolet, visible, or infrared light without cleavage of the fluorophore, phosphorophore, chemiluminescent chromophore or light-producing molecule from cobalamin.
2. The fluorescent cobalamin of claim 1, wherein the fluorophore, phosphorophore, chemiluminescent chromophore or light-producing molecule is attached to the ribose hydroxyl of cobalamin directly or via a linker molecule.
3. The fluorescent cobalamin of claim 1, wherein the fluorophore, phosphorophore, chemiluminescent chromophore or light-producing molecule is attached to a carboxylate derived from one of the amides on the corrin ring directly or via a linker molecule.
4. The fluorescent cobalamin of claim 1, wherein the fluorophore, phosphorophore, chemiluminescent chromophore or light-producing molecule is attached to the cobalt atom of cobalamin directly or via a linker molecule.
5. The fluorescent cobalamin of claim 1 having the general formula

-21-



where R_1 is CN, OH, OH_2 , CH_3 , 5'-deoxyadenosine or $(CH_2)_pNHC(=S)Y$; R_2 , R_3 , R_4 , R_5 , R_6 , and R_7 are independently $CONH_2$ or $CO-X_mY$; R_8 is CH_2OH or $O(C=O)X_mY$; R_9 is OH or $O(C=O)X_mY$; X is a linker having the formula $N(CH_2)_nNHO(C=O)$; Y is a fluorophore, a phosphorophore, chemiluminescent chromophore or a light-producing molecule; m is 0 or 1, n is 0-50 and p is 2-10, with the proviso that at least one of $R_1 - R_9$ groups contains Y.

- 5
6. A method for the identification of cancer tissue or tissue containing cancerous cells of an individual which comprises contacting the fluorescent cobalamin of any one of claims 1-5 with tissue suspected of being cancerous or containing cancerous cells, illuminating said tissue with light, and detecting the emitted fluorescence, phosphorescence or luminescence.
- 10
7. The method of claim 6, wherein said tissue suspected of containing cancerous cells is a lymph node.
- 15

8. The method of claim 7, wherein said lymph node is a sentinel lymph node.
9. The method of claim 7, wherein said lymph node is an axillary lymph node.
- 5 10. The method of claim 6, where the fluorescent cobalamin is injected into a lymph duct.
11. The method of claim 6, wherein the identification is performed with microscopy.
- 10 12. The method of claim 6, wherein the identification is performed visually.
13. The method of claim 6, wherein the identification is performed transdermally.
14. The method of claim 6, wherein said sample is obtained from said individual by biopsy.
- 15 15. A method for visually differentiating cancerous tissue from healthy tissue of an individual which comprises contacting the fluorescent cobalamin of any one of claims 1-5 with tissue from said individual, illuminating said tissue and visually detecting fluorescence, phosphorescence or luminescence, whereby said cancerous tissue fluoresces, phosphoresces or luminesces and said healthy tissue exhibits less fluorescence, phosphorescence or luminescence.
- 20 16. A method for defining tumor margins *in vivo*, *ex vivo*, or *in situ* which comprises contacting the fluorescent cobalamin of any one of claims 1-5 with tissue from said individual suspected of containing a tumor, illuminating said tissue and detecting fluorescence, phosphorescence or luminescence, whereby said tumor tissue fluoresces, phosphoresces or luminesces and defines the margin of the tumor.
- 25 17. A method for identifying metastatic cancer in an individual which comprises contacting the fluorescent cobalamin of any one of claims 1-5 with tissue or cells suspected of being metastatic cancer from said individual, illuminating said tissue and detecting
- 30

-23-

fluorescence, phosphorescence or luminescence, whereby said metastatic cancer tissue or cells fluoresce, phosphoresce or luminesce.

18. The method of claim 17, wherein the identification is performed visually.
- 5
19. The method of claim 17, wherein the identification is performed transdermally.
20. The method of claim 17, wherein the identification is performed microscopically.
- 10
21. A method to diagnose, detect, prognose, predict, or monitor cancer *in vivo*, *ex vivo*, or *in situ* which comprises contacting the fluorescent cobalamin of any one of claims 1-5 with tissue or cells from said individual, illuminating said tissue and detecting fluorescence, phosphorescence or luminescence, whereby cancer tissue or cells fluoresce, phosphoresce or luminesce and healthy tissue exhibits less fluorescence, phosphorescence or luminescence.
- 15
22. The method of claim 21, wherein the contacting is performed by administering the fluorescent cobalamin to said individual intravenously, intrathecally, intramuscularly, intratumorally, intralymphatically or orally.
- 20
23. The method of claim 22, wherein the contacting is performed intraoperatively.
24. The method of claim 23, wherein the contacting is performed in the course of a clinical pathology evaluation of tissue and cells.
- 25
25. A method to identify metastatic disease in the treatment, diagnosis, detection, prediction, prognostication, or monitoring of cancer in an individual which comprises contacting the fluorescent cobalamin of any one of claims 1-5 with tissue or cells from said individual, illuminating said tissue and detecting fluorescence, whereby cancer tissue or cells fluoresce, phosphoresce or luminesce and healthy tissue exhibits less fluorescence, phosphorescence or luminescence..
- 30

26. The method of claim 25, wherein said cancer is breast cancer.
27. The method of claim 25, wherein said cancer is colon cancer.
- 5 28. The method of claim 25, wherein said cancer is ovarian cancer.
29. The method of claim 25, wherein said cancer is lung cancer.
30. The method of claim 25, wherein said cancer is prostate cancer.
- 10 31. The method of claim 25, wherein said cancer is carcinoma that has spread via the lymphatic system.
32. The method of claim 25, wherein said cancer is liver cancer.
- 15 33. The method of claim 25, wherein said cancer is melanoma.
34. The method of claim 25, wherein said cancer is lymphoma.
- 20 35. The method of claim 34, wherein said tissue is bone marrow aspirate.
36. The method of claim 34, wherein said tissue is peripheral blood.
37. The method of claim 25, wherein said cancer is leukemia.
- 25 38. The method of claim 37, wherein said tissue is bone marrow aspirate.
39. The method of claim 38, wherein said tissue is peripheral blood.
- 30 40. The method of claim 25, which utilizes flow cytometry.
41. The method of claim 25, which utilizes automatic analysis of body fluids.

42. A method to predict the response of cancer cells to treatment which comprises contacting the fluorescent cobalamin of any one of claims 1-5 with cancer cells, illuminating said cells and detecting fluorescence, whereby cancer cells which exhibit a greater
5 fluorescence, phosphorescence or luminescence than non-cancerous cells will respond favorably to treatment with a cobalamin-based chemotherapeutic agent.
43. The method of claim 42, wherein said treatment is chemotherapy.
- 10 44. The method of claim 43, wherein said chemotherapy utilizes a cobalamin-therapeutic conjugate.
45. The method of claim 42, wherein said treatment is hormonal therapy.
- 15 46. A method to determine the stage of cancer progression which comprises contacting the fluorescent cobalamin of any one of claims 1-5 with cancer cells, illuminating said cancer cells, and detecting fluorescence, phosphorescence or luminescence whereby the response of cancer cells to cobalamin-based therapy is directly proportional to the fluorescence, phosphorescence or luminescence of said cancer cells compared to non-
20 cancerous cells.
- 47 A method to assay an amount of cobalamin in a sample which comprises performing a competitive binding assay on said sample using a fluorescent cobalamin of any one of claims 1-5 and determining the amount of cobalamin present in said sample.
- 25 48. A method to assay an amount of unsaturated cobalamin binding capacity in a sample which comprises performing a competitive binding assay on cobalamin binding proteins isolated from said sample using a fluorescent cobalamin of any one of claims 1-5 and determining the amount of unsaturated cobalamin binding capacity in said sample.
- 30 49. A method to assay an amount of cobalamin bound to cobalamin binding proteins in a sample which comprises performing a competitive binding assay of cobalamin separated

-26-

from cobalamin binding proteins isolated from said sample using a fluorescent cobalamin of any one of claims 1-5 and determining the amount of cobalamin bound to said proteins in said sample.





Figure 1




Figure 2




Figure 3




Figure 4




Figure 5

专利名称(译)	荧光钴胺素及其用途		
公开(公告)号	EP1226153A2	公开(公告)日	2002-07-31
申请号	EP2000973834	申请日	2000-10-26
[标]申请(专利权)人(译)	犹他大学研究基金会		
申请(专利权)人(译)	UTAH研究基金会大学		
当前申请(专利权)人(译)	UTAH研究基金会大学		
[标]发明人	GRISSOM CHARLES B WEST FREDERICK G MCGREEVY JAMES BENTZ JOEL S		
发明人	GRISSOM, CHARLES, B. WEST, FREDERICK, G. MCGREEVY, JAMES BENTZ, JOEL, S.		
IPC分类号	G01N33/532 A61B10/00 A61K49/00 C07D487/22 C07F15/06 C09K11/06 C12Q1/02 G01N21/76 G01N33/52 G01N33/543 G01N33/566 G01N33/574 G01N33/58 G01N33/68 C07H23/00 G01N33/53		
CPC分类号	A61K49/0052 A61B5/415 A61B5/417 A61B5/418 A61K47/551 A61K49/0013 A61K49/0015 A61K49/0041 A61K49/0043 C07F15/065 C09K11/06 G01N33/52 G01N33/574 G01N2800/52		
优先权	60/161368 1999-10-26 US		
其他公开文献	EP1226153A4 EP1226153B1		
外部链接	Espacenet		

摘要(译)

本发明涉及荧光钴胺素和这些化合物的用途。更具体地，本发明涉及荧光钴胺素，其包含与钴胺素共价连接的荧光，磷光，发光或发光化合物。这些荧光钴胺素可用作诊断和预后标志物 (a) 以区分癌细胞和组织与健康细胞和组织，以及 (b) 确定个体是否将使用钴胺素治疗性生物缀合物对化疗呈阳性反应。